PNV

POLYNOVO FPO [PNV]
PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, and Hong Kong. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; Beta Cell implant, a novel intracutaneous ectopic pancreas to treat type 1 diabetes; NovoSorb MTX for single stage grafting in burns, chronic, and surgical wounds; and plastics and reconstructive device products. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.
Healthcare · ASX Small Cap
$0.9700 -1.0%

Updated 21 Jul 2026 · Signals refresh every scan

Get alerts when PNV triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track PNV — Free

Active Signals

Bullish Signals

  • RSI drifting toward oversold territory — worth watching
  • Drifting lower — down 5.4% over the last 5 days
  • Volume-price trend suggests distribution — sellers may be sneaking out while price holds
  • Cash positive / operating cashflow positive
  • Low P/S ratio (4.9x)
  • Moderate revenue growth (+18%)
  • Piotroski F-Score strong (8/9, low-confidence approx)
  • EPS estimates revised upward (+10pts)
  • Near 52-week low (14% of range)
  • New substantial holder(s) (1)
  • Substantial holder(s) ceased (2)
  • Elevated short interest (8.7%)
  • Earnings in sharp decline (-100% QoQ)
  • CANSLIM A: Turned profitable
  • CANSLIM I: Institutional ownership (38%)
  • Sentiment is mixed — no strong consensus either way
  • Earnings are trending the right way — 2 consecutive improvements
  • Days to cover very high (37.8)
  • Beneish M-Score -1.92 (grey zone -2.22 to -1.78): possible earnings manipulation
  • RBA hiking (-3pts)

Risk Signals

  • Trading below both moving averages — the trend is working against this one
  • Below the 200-day average — the long-term trend is still working against it
  • Post-earnings drift: negative surprise (SUE -10)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Long-term momentum is negative — down 34% over the past year
Ask Scout AI about PNV
"What's driving PNV today?" "How does PNV compare to peers?" "Key risks for PNV?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Change in substantial holding
NONE Change in substantial holding
HIGH Becoming a substantial holder
HIGH Ceasing to be a substantial holder
HIGH Ceasing to be a substantial holder

Recent ASX Announcements

2026-06-29 Change in substantial holding
2026-06-24 Becoming a substantial holder
2026-06-23 Ceasing to be a substantial holder
2026-06-22 Change in substantial holding
2026-06-05 Ceasing to be a substantial holder

Key Metrics

$677.0M
Market Cap
1.6M
Avg Volume
0.8x
Vol Ratio
$0.86 — $1.67
52-Week Range
8.7%
Short Interest
N/A
Cash Runway
12.5%
ROE
7.1%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: -100%
AAnnual EarningsimprovingCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 89%
LLeader vs LaggardlaggardRS: -1
IInstitutional SponsorshippassInst: 38%
MMarket DirectionneutralNeutral

Sector: Healthcare

111 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
ECS +20.0%VHL -15.4%NTI +12.5%PIQ -11.4%OSL -10.3%
Compare:PNV vs ECSPNV vs VHLPNV vs NTI
Scout Pro — Deeper Analysis for PNV
Try Pro free for 30 days
Share this analysis

Track PNV and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required